SG11202105911PA - Usp19 inhibitors for use in therapy - Google Patents
Usp19 inhibitors for use in therapyInfo
- Publication number
- SG11202105911PA SG11202105911PA SG11202105911PA SG11202105911PA SG11202105911PA SG 11202105911P A SG11202105911P A SG 11202105911PA SG 11202105911P A SG11202105911P A SG 11202105911PA SG 11202105911P A SG11202105911P A SG 11202105911PA SG 11202105911P A SG11202105911P A SG 11202105911PA
- Authority
- SG
- Singapore
- Prior art keywords
- hydroxy
- methyl
- phenyl
- dihydropyridine
- azaspiro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1819936.4A GB201819936D0 (en) | 2018-12-06 | 2018-12-06 | Therapeutic methods |
| GBGB1904341.3A GB201904341D0 (en) | 2019-03-28 | 2019-03-28 | Therapeutic methods |
| PCT/GB2019/053456 WO2020115500A1 (en) | 2018-12-06 | 2019-12-06 | Usp19 inhibitors for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105911PA true SG11202105911PA (en) | 2021-07-29 |
Family
ID=68887434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105911PA SG11202105911PA (en) | 2018-12-06 | 2019-12-06 | Usp19 inhibitors for use in therapy |
Country Status (12)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3134564A1 (en) * | 2019-05-06 | 2020-11-12 | Lawrence Marcin | Inhibiting usp19 |
| GB202104097D0 (en) * | 2021-03-24 | 2021-05-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB202311227D0 (en) | 2023-07-21 | 2023-09-06 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO111096A0 (en) * | 1996-07-18 | 1996-08-08 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| WO2009072643A1 (en) | 2007-12-03 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use thereof |
| CN104174021A (zh) * | 2013-05-22 | 2014-12-03 | 复旦大学附属华山医院 | 蛋白酶体抑制剂在制备治疗慢性低度炎症性疾病药物中的用途 |
| TWI698436B (zh) * | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
| GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| AU2018342089B2 (en) * | 2017-09-26 | 2024-07-11 | Dana-Farber Cancer Institute, Inc. | Novel USP7 inhibitors for treating multiple myeloma |
| GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
-
2019
- 2019-12-06 JP JP2021532119A patent/JP2022510700A/ja active Pending
- 2019-12-06 CN CN201980091404.7A patent/CN113395965A/zh active Pending
- 2019-12-06 AU AU2019393161A patent/AU2019393161A1/en not_active Abandoned
- 2019-12-06 KR KR1020217019978A patent/KR20210100127A/ko not_active Withdrawn
- 2019-12-06 SG SG11202105911PA patent/SG11202105911PA/en unknown
- 2019-12-06 CA CA3121422A patent/CA3121422A1/en active Pending
- 2019-12-06 MX MX2021006542A patent/MX2021006542A/es unknown
- 2019-12-06 EP EP19821175.7A patent/EP3890737B1/en active Active
- 2019-12-06 US US17/299,971 patent/US20220016115A1/en not_active Abandoned
- 2019-12-06 BR BR112021010645-6A patent/BR112021010645A2/pt not_active IP Right Cessation
- 2019-12-06 WO PCT/GB2019/053456 patent/WO2020115500A1/en not_active Ceased
-
2021
- 2021-06-03 IL IL283687A patent/IL283687A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020115500A1 (en) | 2020-06-11 |
| AU2019393161A1 (en) | 2021-06-17 |
| EP3890737A1 (en) | 2021-10-13 |
| IL283687A (en) | 2021-07-29 |
| EP3890737B1 (en) | 2024-06-05 |
| CA3121422A1 (en) | 2020-06-11 |
| MX2021006542A (es) | 2021-07-07 |
| BR112021010645A2 (pt) | 2021-08-17 |
| KR20210100127A (ko) | 2021-08-13 |
| US20220016115A1 (en) | 2022-01-20 |
| CN113395965A (zh) | 2021-09-14 |
| JP2022510700A (ja) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4440642B2 (ja) | ピリミジンA2b選択的アンタゴニスト化合物、それらの合成、及び使用 | |
| JP6986065B2 (ja) | 医薬化合物 | |
| TWI582079B (zh) | σ配體類於與第2型糖尿病有關之疼痛上之用途 | |
| US7087608B2 (en) | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy | |
| US10875863B2 (en) | RIPK2 inhibitors and method of treating cancer with same | |
| AU2011237421B2 (en) | Inverse agonists and neutral antagonists for the TSH receptor | |
| EP3890737B1 (en) | Usp19 inhibitors for use in a method of treating obesity, insulin resistance and type ii diabetes | |
| EP4587429B1 (en) | Substituted oxoisoindolinyl piperidine-2,6-dione compounds | |
| TW201022234A (en) | Pyrrolidines | |
| US20240327382A1 (en) | Pharmaceutical compounds as inhibitors of ubiquitin specific protease 19 | |
| US20220033397A1 (en) | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) | |
| WO2025021711A1 (en) | Pharmaceutical compounds | |
| WO2025108404A1 (zh) | 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途 |